Krystal Biotech(KRYS)
$315.34+16.79 (+5.62%)
KRYS
Krystal Biotech financials statements
$315.34
At close:+16.79 (+5.62%)
Want to see KRYS full AI Analyst Report?
Krystal Biotech (KRYS) Ratios
738 Followers
Krystal Biotech Ratios
KRYS's free cash flow for Q3 2026 was $90.25M. For the 2026 fiscal year, KRYS's free cash flow was decreased by $-996.00K and operating cash flow was $91.25M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 9.95 | 7.28 | 17.76 | 13.30 | 17.18 |
| Quick Ratio | 9.56 | 7.02 | 17.55 | 13.30 | 17.18 |
| Cash Ratio | 4.82 | 3.38 | 10.83 | 5.61 | 13.26 |
| Solvency Ratio | 1.85 | 0.88 | 0.42 | -3.77 | -2.07 |
| Operating Cash Flow Ratio | 1.95 | 1.21 | -2.68 | -3.49 | -1.86 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 910.37M | $ 632.59M | $ 548.20M | $ 347.56M | $ 409.55M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| Debt-to-Equity Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| Debt-to-Capital Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.12 | 1.05 | 1.07 | 1.06 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -44.39 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -45.76 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.32 | 0.25 | 0.30 | 0.35 | 0.43 |
| Net Debt to EBITDA | -2.48 | -3.07 | 3.84 | 1.31 | 5.03 |
| Profitability Margins | |||||
| Gross Profit Margin | 92.61% | 93.09% | 93.90% | 0.00% | 0.00% |
| EBIT Margin | 48.69% | 35.52% | -191.77% | 0.00% | 0.00% |
| EBITDA Margin | 50.37% | 37.83% | -180.11% | 0.00% | 0.00% |
| Operating Profit Margin | 41.45% | 22.61% | -216.43% | 0.00% | 0.00% |
| Pretax Profit Margin | 48.69% | 32.82% | 25.44% | 0.00% | 0.00% |
| Net Profit Margin | 52.64% | 30.69% | 21.56% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 52.64% | 30.69% | 21.56% | 0.00% | 0.00% |
| Net Income Per EBT | 108.11% | 93.50% | 84.76% | 100.00% | 100.00% |
| EBT Per EBIT | 117.47% | 145.15% | -11.75% | 96.40% | 101.90% |
| Return on Assets (ROA) | 15.36% | 8.44% | 1.34% | -25.06% | -11.11% |
| Return on Equity (ROE) | 16.80% | 9.42% | 1.40% | -26.80% | -11.72% |
| Return on Capital Employed (ROCE) | 13.10% | 6.89% | -13.97% | -27.42% | -11.37% |
| Return on Invested Capital (ROIC) | 13.09% | 6.43% | -11.82% | -27.34% | -11.35% |
| Return on Tangible Assets | 15.36% | 8.44% | 1.34% | -25.06% | -11.11% |
| Earnings Yield | 2.87% | 1.99% | 0.32% | -6.93% | -4.48% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.05 | 2.77 | 1.21 | 0.00 | 0.00 |
| Payables Turnover | 8.89 | 4.02 | 1.67 | 0.00 | 0.00 |
| Inventory Turnover | 0.71 | 0.76 | 0.44 | 0.00 | 0.00 |
| Fixed Asset Turnover | 2.46 | 1.80 | 0.30 | 0.00 | 0.00 |
| Asset Turnover | 0.29 | 0.28 | 0.06 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.50 | 0.49 | 0.11 | 0.00 | 0.00 |
| Cash Conversion Cycle | 591.89 | 523.20 | 908.56 | 0.00 | 0.00 |
| Days of Sales Outstanding | 119.52 | 131.60 | 302.66 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 513.45 | 482.30 | 824.02 | 0.00 | 0.00 |
| Days of Payables Outstanding | 41.08 | 90.70 | 218.13 | 0.00 | 0.00 |
| Operating Cycle | 632.97 | 613.90 | 1126.68 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 6.94 | 4.32 | -3.27 | -3.95 | -2.16 |
| Free Cash Flow Per Share | 6.53 | 4.17 | -3.70 | -6.02 | -5.24 |
| Dividend Paid and CapEx Coverage Ratio | 16.81 | 29.12 | -7.53 | -1.90 | -0.70 |
| Capital Expenditure Coverage Ratio | 16.81 | 29.12 | -7.53 | -1.90 | -0.70 |
| Operating Cash Flow Coverage Ratio | 21.51 | 17.00 | -10.97 | -11.26 | -5.97 |
| Operating Cash Flow to Sales Ratio | 0.52 | 0.42 | -1.75 | 0.00 | 0.00 |
| Free Cash Flow Yield | 2.65% | 2.66% | -2.99% | -7.60% | -7.49% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 34.82 | 50.21 | 308.15 | -14.43 | -22.32 |
| Price-to-Sales (P/S) Ratio | 18.34 | 15.42 | 66.45 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 5.85 | 4.73 | 4.33 | 3.87 | 2.62 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 37.77 | 37.58 | -33.49 | -13.15 | -13.35 |
| Price-to-Operating Cash Flow Ratio | 35.53 | 36.29 | -37.93 | -20.08 | -32.39 |
| Price-to-Earnings Growth (PEG) Ratio | 0.27 | 0.07 | -2.87 | -0.19 | -0.27 |
| Enterprise Value Multiple | 33.92 | 37.68 | -33.06 | -15.98 | -18.41 |
| Enterprise Value | 6.65B | 4.14B | 3.02B | 1.87B | 1.22B |
| EV to EBITDA | 33.92 | 37.68 | -33.06 | -15.98 | -18.41 |
| EV to Sales | 17.09 | 14.26 | 59.54 | 0.00 | 0.00 |
| EV to Free Cash Flow | 35.20 | 34.75 | -30.00 | -12.16 | -10.49 |
| EV to Operating Cash Flow | 33.10 | 33.56 | -33.99 | -18.56 | -25.44 |
| Tangible Book Value Per Share | 42.14 | 33.10 | 28.68 | 20.49 | 26.74 |
| Shareholders’ Equity Per Share | 42.14 | 33.10 | 28.68 | 20.49 | 26.74 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.08 | 0.06 | 0.15 | 0.00 | 0.00 |
| Revenue Per Share | 13.44 | 10.16 | 1.87 | 0.00 | 0.00 |
| Net Income Per Share | 7.08 | 3.12 | 0.40 | -5.49 | -3.13 |
| Tax Burden | 1.08 | 0.94 | 0.85 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.92 | -0.13 | 1.16 | 1.02 |
| Research & Development to Revenue | 0.15 | 0.18 | 0.92 | 0.00 | 0.00 |
| SG&A to Revenue | 0.38 | 0.39 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.14 | 0.17 | 0.79 | 0.00 | 0.00 |
| Income Quality | 0.98 | 1.38 | -8.12 | 0.72 | 0.69 |
Currency in USD

